I just posted the attached comments to the public docket FDA opened up in advance of the advisory committee meeting to review Pfizer's application for emergency use authorization for its COVID-19 vaccine. At some point, I will review and summarize all the comments posted to the docket, but that won't be any time real soon.
------------------------------
Julie Omohundro, ex-RAC (US, GS), still an MBA
Principal Consultant
Class Three, LLC
Mebane, North Carolina, USA
919-544-3366 (T)
434-964-1614 (C)
julie@class3devices.com------------------------------